AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00842257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Panitumumab is administered intravenously (IV) by an infusion pump through a peripheral line or indwelling catheter using a 0.2 or 0.22-micron in-line filter infusion set-up over 1 hour 15 minutes. The starting panitumumab dose is 6 mg/kg administered every 14 days for as long as patients are on study without evidence of disease progression or demonstrating intolerance to treatment. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual body weight at each visit. Panitumumab will be diluted in a minimum of 100 mL of pyrogen-free 0.9% sodium chloride solution (normal saline solution, supplied by the site). The maximum concentration of the diluted solution to be infused should not exceed 10 mg/mL.
Study NCT01795144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
Study NCT01795144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
Study NCT01795144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin 9-39
Description: OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
Study NCT01795144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin 9-39
Description: OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
Study NCT03229707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital photography using software Photoshop
Description: When taking the image, a gray card is used for subsequent exposure calibration in Adobe Camera Raw (which is packaged with Photoshop).~* Images are then opened into Photoshop.~* The INFO panel must be open.~* Click on the small eyedropper in the Info panel window and click on ''Lab Color.~* Place the mouse over the center of the tooth to be measured for L value.~* Click on the HSB Color option, which stands for hue, saturation, and brightness.
Study NCT03229707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vita 3D master shade guide
Description: Alpha (A)Perfectly matched Beta (B)Not perfectly matched Charlie (C)unacceptable Determent by 10 observers
Study NCT03694288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant removal
Description: Surgical Implant removal
Study NCT03126812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC=6
Study NCT03126812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 80 mg/m2
Study NCT03126812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg flat dose, starting cycle 2
Study NCT03988569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: audiovisual decision aid
Description: Will view AVDA and then have opportunity for questions with physician before signing consent forms
Study NCT03795428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemziviptadil (PB1046) Injection
Description: Once-weekly subcutaneous injection
Study NCT04440046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy thoracic spine
Description: Manual therapy mobilization directed to the costovertebral joint.
Study NCT04440046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy glenohumeral joint
Description: Manual therapy mobilization directed to the glenohumeral joint.
Study NCT04440046 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manual therapy glenohumeral joint
Description: Manual therapy mobilization directed to the glenohumeral joint.
Study NCT04440046 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham thoracic manual therapy
Description: Sham manual therapy directed to the costovertebral joint.
Study NCT04440046 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham glenohumeral manual therapy
Description: Sham manual therapy directed to the glenohumeral joint.
Study NCT04440046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Therapeutic exercise program consisting on isometric exercise with progressive load.
Study NCT04440046 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Therapeutic exercise
Description: Therapeutic exercise program consisting on isometric exercise with progressive load.
Study NCT04439799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Cypionate 200 Mg/ML
Description: Participants in this group will receive intramuscular testosterone cypionate injections of 1 cc (200mg) once every 14 days for four months.
Study NCT04439799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Testosterone
Description: Participant in this group will receive Intranasal testosterone administered using a multi-dose dispenser, as two or three daily doses (5.5 mg per nostril, 11.0 mg single dose) for 4 consecutive months,
Study NCT00099619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide/insulin glargine
Description: Subcutaneously injected exenaide 10 mcg twice daily for 16 weeks; then insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels
Study NCT00099619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine/exenatide
Description: Subcutaneously injected insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels; then exenaide 10 mcg twice daily for 16 weeks
Study NCT01391130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2510924
Description: Administered subcutaneously
Study NCT01391130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Administered orally
Study NCT01391130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Administered orally
Study NCT04108754 — intervention group
Intervention type: OTHER
Intervention: microangiopathic burden
Description: to determine the value of the global microangiopathic burden on the prediction of early stroke risk in a homogeneous cohort of TIA.
Study NCT02274896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PD Catheter group
Description: PD catheter
Study NCT02698007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Description: Fiberoptic bronchoscopy with the use of LMA
Study NCT02805439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S47445 15mg
Description: One tablet of S47445 15 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
Study NCT02805439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S47445 50mg
Description: One tablet of S47445 50 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
Study NCT02805439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet of placebo taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
Study NCT01145170 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be given at the standard dose between 54 and 60 Gy for irradiation of tumors of the central nervous system.
Study NCT01145170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: The patients will receive the induction therapy for 12 weeks. If the patient reaches a complete, partial response (CR, PR) to the treatment or is at least evaluated as stable disease (SD) on week 12, the consolidation therapy should be initiated. The consolidation therapy will consist of the nimotuzumab administration, every 2 weeks.
Study NCT01234844 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: care of guinea pigs
Description: twice weekly sessions of care with guinea pigs
Study NCT01234844 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: guinea pigs
Description: twice weekly pet therapy and twice weekly usual  occupational therapy
Study NCT02129582 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow irradiation
Description: Undergo TMI
Study NCT02129582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT02129582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV or PO
Study NCT02129582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: myeloid progenitor cell transplantation
Description: Undergo allogeneic hematopoietic progenitor cell transplant
Study NCT02129582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV
Study NCT02129582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO
Study NCT02129582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT02129582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00880048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orvepitant
Description: neurokinin-1 antagonist
Study NCT00880048 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match orvepitant 30 mg and 60 mg
Study NCT03471611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CD34+ Cells
Description: The dose will be 1x10\^5 cells/kg, injected at the rate of 10 ml/min
Study NCT03471611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF)
Description: 5mg/kg twice daily
Study NCT02768571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Cerebrolysin- cerebrolysin 30 ml with 100 ml dilution/day \* 21 days with rehabilitation
Study NCT02768571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo- saline 100 ml/day \* 21 days with rehabilitation
Study NCT05480358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fasting-Mimicking Diet ProlonADTM
Description: Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
Study NCT05480358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting-Mimicking Diet ProlonADTM
Description: Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
Study NCT00427752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transgastric endoscopic peritoneoscopy.
Description: Exploration of the abdominal area
Study NCT01932450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal sympathetic denervation
Description: One-time standard Catheter-based renal sympathetic denervation will be performed in both renal arteries by radiofrequency ablation.
Study NCT01932450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antihypertensive drugs
Description: antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
Study NCT04641312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3457263
Description: Administered SC
Study NCT04641312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC
Study NCT04311151 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: own seizures visualization
Description: At the hospital discharge, patients
Study NCT03128736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole group
Description: Esomeprazole 40mg qd
Study NCT04641312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC
Study NCT04641312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT00783211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: desloratadine, 5 mg oral tablets, once daily for 15 days
Study NCT00783211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fexofenadine
Description: fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
Study NCT00783211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, once daily for 15 days
Study NCT03146052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-4000 added with citrates and simethicone (PEG-CS) plus Bisacodyl
Description: PEG-4000 added with citrates and simethicone (PEG-CS) (Kit contains 4 pouches, each containing 64.5gr of PEG) and bisacodyl 5 mg tablets
Study NCT03146052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-4000 added with citrates and simethicone (PEG-CS) plus Bisacodyl
Description: PEG-4000 added with citrates and simethicone (PEG-CS) (Kit contains 4 pouches, each containing 64.5gr of PEG) and bisacodyl 5 mg tablets
Study NCT01932450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihypertensive drugs
Description: antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
Study NCT04258059 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active household UV water treatment device
Description: This point-of-entry treatment device will use germicidal UV to treat all of the well water used in the home.
Study NCT04258059 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive household UV water treatment device
Description: This sham device will use a lamp not emitting germicidal UV.
Study NCT01870024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam
Description: clonazepam 0,015 mg/kg
Study NCT01870024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosphenytoin
Description: fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
Study NCT01870024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
Study NCT03128736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole group
Description: Dexlansoprazole 60mg qd
Study NCT04286919 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A Randomized Controlled Trial Comparing the Physical Activity Guidelines for Americans to a New Method of Exercise Prescription Among College Students
Description: A randomized controlled trial comparing the 2018 Physical Activity Guidelines for Americans weekly recommendations of 150-minutes of moderate intensity physical activity plus 2 days of muscle-strengthening physical activity to the Move Your Way Campaign message of increasing any and all physical activity to accumulate more movement throughout the week across all types and intensities.
Study NCT04286919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Randomized Controlled Trial Comparing the Physical Activity Guidelines for Americans to a New Method of Exercise Prescription Among College Students
Description: A randomized controlled trial comparing the 2018 Physical Activity Guidelines for Americans weekly recommendations of 150-minutes of moderate intensity physical activity plus 2 days of muscle-strengthening physical activity to the Move Your Way Campaign message of increasing any and all physical activity to accumulate more movement throughout the week across all types and intensities.
Study NCT03027921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elastography
Study NCT03329976 — intervention group
Intervention type: OTHER
Intervention: measurement of visual acuity
Description: complete ophthalmologic examination of a macular SD-OCT, a fundus of eye, evaluation of the vision of contrasts (Pelli-Robson test) and quantification of metamorphopsies (M-Charts);
Study NCT01201759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days
Description: Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2
Study NCT01870024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)
Study NCT00923234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles
Study NCT00923234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
Study NCT04496791 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIC (Receiver in Canal) hearing aid/ hearing instrument (HI)
Description: HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
Study NCT04496791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC (Receiver in Canal) hearing aid/ hearing instrument (HI)
Description: HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
Study NCT05099146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pictures
Description: pictures with brushing technique demonstrated technique for proper brushing
Study NCT05099146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video
Description: video of brushing technique demonstrated technique for proper brushing
Study NCT05099146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control
Description: oral hygiene instructions provided
Study NCT02817152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal ultrasonic debridement
Description: Periodontal pockets received periodontal ultrasonic debridement intervention.
Study NCT02817152 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Periodontal ultrasonic debridement
Description: Periodontal pockets received periodontal ultrasonic debridement intervention.
Study NCT02817152 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement plus low-level laser therapy
Description: Ultrasonic debridement plus low-level laser therapy.
Study NCT04021394 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CellSearch CTC platform
Description: epithelial-based marker approach for immunomagnetic enrichment, isolation, and quantitative immunofluorescence of CTCs
Study NCT04021394 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Parsortix CTC platform
Description: EMT-independent platform
Study NCT01637662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natriuretic peptides
Description: I.V. infusion between 0.2-3 microgram over 20 minutes
Study NCT01230840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: wheat dextrin
Description: 5 grams of wheat dextrin baked in cookies will be taken 3 times a day for 2 weeks
Study NCT01230840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: cookies not containing wheat dextrin will be taken 3 times a day for 2 weeks
Study NCT04610008 — intervention group
Intervention type: OTHER
Intervention: No intervention. Purely observation
Description: Retrospective image analysis of the shape of the optic nerve head in both groups
Study NCT01201759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.
Description: Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.